These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31870220)

  • 1. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase.
    Wu X; Li Q; Wan S; Zhang J
    J Biomol Struct Dyn; 2021 Jan; 39(1):202-208. PubMed ID: 31870220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
    Bagal SK; Omoto K; Blakemore DC; Bungay PJ; Bilsland JG; Clarke PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; Johnson E; Fengas D; Kitching L; Kraus ML; McAlpine I; Nagata A; Waldron GJ; Warmus JS
    J Med Chem; 2019 Jan; 62(1):247-265. PubMed ID: 29672039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue.
    Furuya N; Momose T; Katsuno K; Fushimi N; Muranaka H; Handa C; Sawa M; Ozawa T; Kinoshita T
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126775. PubMed ID: 31699609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
    Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
    Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies.
    Guo J; Xiang S; Wang J; Zhou Y; Wang Z; Zhang Z; Ding K; Lu X
    Eur J Med Chem; 2022 Jan; 228():114022. PubMed ID: 34871843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand.
    Ivanisevic L; Zheng W; Woo SB; Neet KE; Saragovi HU
    J Biol Chem; 2007 Jun; 282(23):16754-63. PubMed ID: 17439940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of neurotrophin-3 to p75LNGFR, TrkA, and TrkB mediated by a single functional epitope distinct from that recognized by trkC.
    Rydén M; Ibáñez CF
    J Biol Chem; 1996 Mar; 271(10):5623-7. PubMed ID: 8621424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
    Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of the transmembrane domain dimerization and rotation in the activation mechanism of the TRKA receptor by nerve growth factor.
    Franco ML; Nadezhdin KD; Goncharuk SA; Mineev KS; Arseniev AS; Vilar M
    J Biol Chem; 2020 Jan; 295(1):275-286. PubMed ID: 31801826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity.
    Furuya N; Momose T; Katsuno K; Fushimi N; Muranaka H; Handa C; Ozawa T; Kinoshita T
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1233-1236. PubMed ID: 28159414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains.
    Zaccaro MC; Ivanisevic L; Perez P; Meakin SO; Saragovi HU
    J Biol Chem; 2001 Aug; 276(33):31023-9. PubMed ID: 11425862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells.
    Tam SY; Tsai M; Yamaguchi M; Yano K; Butterfield JH; Galli SJ
    Blood; 1997 Sep; 90(5):1807-20. PubMed ID: 9292513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating specificity of an allosteric inhibitor WNK476 among With-No-Lysine kinase isoforms using molecular dynamic simulations.
    Amarnath Jonniya N; Sk MF; Kar P
    Chem Biol Drug Des; 2021 Sep; 98(3):405-420. PubMed ID: 33969941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of trkA, trkB, and trkC in injured and regenerating retinal ganglion cells of adult rats.
    Cui Q; Tang LS; Hu B; So KF; Yip HK
    Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1954-64. PubMed ID: 12037005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkA amino acids controlling specificity for nerve growth factor.
    O'Connell L; Hongo JA; Presta LG; Tsoulfas P
    J Biol Chem; 2000 Mar; 275(11):7870-7. PubMed ID: 10713102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition.
    Bertrand T; Kothe M; Liu J; Dupuy A; Rak A; Berne PF; Davis S; Gladysheva T; Valtre C; Crenne JY; Mathieu M
    J Mol Biol; 2012 Oct; 423(3):439-53. PubMed ID: 22902478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Insights into the Sequence-Activity Relationships of the NGF(1-14) Peptide by Molecular Dynamics Simulations.
    Vittorio S; Manelfi C; Gervasoni S; Beccari AR; Pedretti A; Vistoli G; Talarico C
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T; Yu D; Lamb ML
    Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo.
    Tang S; Xue Y; Dengqi X; Shao L
    Eur J Med Chem; 2023 Jan; 245(Pt 2):114901. PubMed ID: 36423414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.